Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

Abstract

Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease. Methods: The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA). Results: The cost per responder for ACR 20 was €19,846 versus €19,766 for secukinumab and adalimumab, respectively, whereas the costs per responder for ACR 50 and PASI 90 were €27,820 versus €27,384 and €22,102 versus €32,375 for secukinumab and adalimumab, respectively. The cost per MDA responder was €34,072 and €38,906 for secukinumab versus adalimumab. Conclusions: The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab.

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

“…The treatment of moderate-to-severe psoriasis with biologic agents poses a significant economic burden to healthcare systems [ 6 , 12 , 13 , 44 ]. Despite increasing recognition of the potential of biologic therapies to reduce both direct and indirect healthcare costs in the long term, economic considerations focusing solely on drug acquisition costs mean that they often remain restricted to patients with only the most severe forms of disease.…”

“…Recently, biosimilars have provided a more cost-effective alternative to off-patent biologic therapies within IMIDs, including psoriasis [ 10 , 11 ]. In particular, evidence is mounting to confirm the use of biosimilars as a valuable pharmacoeconomic strategy to lower healthcare cost in patients with psoriasis [ 6 , 12 , 13 ], thereby allowing the use of biologics by a wider group of patients and earlier in the disease course.…”

Advanced Glycation End Products and Psoriasis

“…Both genetic and environmental factors play a relevant role in psoriasis pathogenesis. Most psoriasis susceptibility loci are related to inflammatory and immunity genes [ 4 , 5 , 6 ]. Environmental and triggering factors include infections (including COVID), stressful life events, medications, skin trauma, and air pollution [ 4 , 5 , 6 ].…”

“…Most psoriasis susceptibility loci are related to inflammatory and immunity genes [ 4 , 5 , 6 ]. Environmental and triggering factors include infections (including COVID), stressful life events, medications, skin trauma, and air pollution [ 4 , 5 , 6 ]. Early events in the development of psoriasis lesions include the recruitment and the activation of plasmacytoid dendritic, which together with natural killer cells and macrophages, secrete cytokines such as IFN-γ, IL-1β, and TNF-α.…”

Social Media Content on Immunology: Is an Assessment by the Scientific Community Required?

“…Among the chronic diseases with the highest prevalence, rheumatological diseases are to be counted. Specifically, arthritis is diagnosed in 23% of adult Americans and psoriasis affect 1–4% of the population worldwide [ 6 , 7 ]. Additionally, a recent report by the World Health Organization (WHO), has revealed that infectious diseases, specifically lower respiratory infections, represent the first cause of communicable death worldwide, for both males and females [ 8 ].…”